Earnings ·
Eli Lilly and Company reported second-quarter 2026 financial results on August 5, 2026, announcing a 48%…
LLYELI LILLY & Co
Eli Lilly and Company reported second-quarter 2026 financial results on August 5, 2026, announcing a 48% year-over-year revenue increase to $23.0 billion, driven by strong volume growth in Mounjaro and Zepbound. Reported earnings per share rose 26% to $7.94, while non-GAAP EPS increased 33% to $8.38; both figures included significant acquired IPR&D charges of $3.03 per share related to recent acquisitions. The company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion and updated non-GAAP EPS guidance to $35.50–$36.50, reflecting underlying growth offset by acquisition-related charges. Additionally, Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana and highlighted regulatory approvals for Ebglyss and Jaypirca alongside positive Phase 3 data for retatrutide. Eli Lilly is a global pharmaceutical company focused on discovering, developing, and delivering medicines for diabetes, obesity, oncology, immunology, neuroscience, and other therapeutic areas.